This round is no longer accepting investments, but hundreds just like it are live now.

Log In


Kazu: Health In Tune With You

Kazu brings health and wellness into the future with an AI-enabled, handheld interactive device that dispenses personalized doses of medicines and supplements to achieve better results. The platform includes pods (consumables) and a connected mobile app. With thousands of first-gen units already built and production tooling complete, we are ready to move toward commercialization. The Kazu product is not yet available on the market.

This Reg CF offering is made available through StartEngine Capital, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

$26,763.04 Raised


Our interactive device and AI-enabled platform work with you to dispense precision doses, provide personalized guidance, and track results, improving your health and wellness outcomes.

We have filed ten patents for our technology, manufactured thousands of first-generation units for study purposes, and created production tooling, positioning us to create a new category at the intersection of the multi-billion dollar health technology, medicine, and supplements markets.

The value we deliver increases over time as platform adoption grows and our AI learns from a growing user base, allowing us to continuously offer new and improved services and products as our technology develops.

the pitch

We at Wellness Insight Technologies developed Kazu, a handheld interactive device that dispenses personalized amounts of medicines and supplements to optimize health and wellness. The Kazu platform includes pods (consumables) and an AI-enabled app. Kazu provides personalized dosing insights, tracks progress, and addresses a myriad of the   shortcomings of industrialized medicine. We are initially targeting the millions of self-care consumers who use CBD and melatonin for sleep, stress, relief, and more. Since our launch, we have invested in 5 years of R&D, developed products for pharma companies, filed 10 patents, manufactured thousands of first-generation units, and completed production tooling. The Kazu product is not yet available on the market.


Enabling Precise Personalization of Health and Wellness

*The above is a rendering of the Kazu product that is not yet available on the market.

Kazu brings the connected-health revolution to a range of markets, including natural medicines, dietary supplements, and over-the-counter (OTC) pharmaceuticals. We funded the R&D process through revenue generated from development agreements with a number of pharmaceutical companies. We have manufactured thousands of first-generation units for third-party study purposes and have completed production tooling for the consumer launch version. With this raise, we will make our software user-friendly, secure inventory, and execute our go-to market strategy.

The Problem & Our solution

Personalized Precision Dosing for Improved Outcomes

Personalized medicine achieves better health outcomes through precise doses that are tailored to each individual, but remains too expensive, inaccessible, and even unavailable for many of the most common issues. Moreover, today's industrialized medicine is based on averages, providing a one-size-fits-all approach that may or may not fit with your unique physiology. The result is that many people either overmedicate and waste money or consume too little of what they need to achieve optimal results. 

*The above is a rendering of the Kazu product that is not yet available on the market.

We enable our users to precisely control their own doses with personalized AI-enabled guidance derived from their own unique characteristics. Our platform combines a handheld device with an interactive touchscreen, a variety of pre-filled CBD and melatonin pods, and a Bluetooth-connected mobile app to allow our users to take charge of their own health and wellness.  

the market & Our Traction

Proven Technology at the Intersection of Multiple Major Markets

We are creating a new category that intersects health technology, medicine, and supplements. The closest comparison is the wearable medical device market, projected to reach $196 billion by 2027, with a CAGR of 26.4% (Source). Meanwhile, the natural medicine and dietary supplements market is expected to reach $313 billion by 2028. Within this are our launch categories. The CBD category alone is estimated to reach $56 billion in 2028 with a CAGR of 47.5%, and the sleep aid medication category is projected to grow to $33 billion by 2030 (Source | Source).

Source | Source | Source | Source

*The above is a rendering of the Kazu product that is not yet available on the market.

We have 10 issued and pending patents, 14 design registrations, 5 issued and pending trademarks, and a number of copyrights and trade secrets. After 5 years of R&D, we have manufactured over 12,000 fully functional first-generation pods and devices for study purposes. And our efforts resulted in a partnership announcement for a distinct product with Perrigo, a major pharmaceutical company.  

The Federal Food, Drug, and Cosmetic Act (FDCA) and the Dietary Supplement Health and Education Act (DSHEA) of 1994 define the legal framework for making health claims about dietary supplements. In the United States, dietary supplement manufacturers are allowed to make certain health claims about their products under certain circumstances, but there are strict regulations that must be followed. The Company intends to comply with these regulations. Additionally, the FDA has established good manufacturing practices (GMPs) that companies must follow to help ensure the identity, purity, strength, and composition of their dietary supplements. Wellness Insight Technologies Inc partners with manufacturers and suppliers who have implemented GMPs. However, dietary supplements, including botanicals, do not require FDA approval. Kazu is not a medical device, is not intended to treat illness or disease, and does not dispense FDA approved drugs. The Kazu device does not alter the composition of dietary supplements and botanicals it dispenses. For these reasons, FDA approval of the Kazu device is not required. Should the Company see an opportunity to work with FDA approved drugs in the future, it will undertake the necessary approval process.

Why Invest

The Health and Wellness Technology of Tomorrow, Here Today

Consumer acceptance of personalized health technology is evidenced by the myriad of products that measure our bodies. But we see a huge market gap; none of these products measure and track the medicines and supplements we put into our bodies. Our initial launch will focus on CBD and melatonin in the DTC channel, but we see endless future applications including vitamins, prescription drugs, psychedelics, aromatherapy, and more. In the long term, we envision Kazu setting a new standard for dosing across natural medicines, supplements, and regulated pharmaceuticals. With half a decade of R&D and a standout team of highly experienced leaders and advisors, we are positioned to connect people to their own wellness like never before.


1210 S. Bascom Ave., STE 122
San Jose, CA 95128

Kazu brings health and wellness into the future with an AI-enabled, handheld interactive device that dispenses personalized doses of medicines and supplements to achieve better results. The platform includes pods (consumables) and a connected mobile app. With thousands of first-gen units already built and production tooling complete, we are ready to move toward commercialization. The Kazu product is not yet available on the market.


Ramon Alarcon
Ramon Alarcon
Founder and CEO

Ramon is an entrepreneur with over 25 years of expertise developing ground-breaking consumer technology products, delivering multimillion-dollar growth in domestic and international markets. Ramon has led world-class development teams both at the start-up and growth stages, resulting in successful corporate acquisitions and an IPO. Ramon has deep experience in product manufacturing and supply chain. He is a prolific innovator, being a named inventor on over 100 domestic and international patents. He is a leading expert in inhalation technology and has presented to the FDA and developed safety standards with UL.

Rick Conrey

Rick Conrey

Director of Software Development (Part-Time)

Rick is a rockstar developer. He brings over a decade of experience in designing first-rate embedded systems, working on a broad range of products from resource constrained devices to large 7-passenger vehicles. He gained his experience in different industries, vaporizers at blu, electric vehicles ar INO, audio at Velodyne Acoustics, and more. Rick has also built desktop and full stack web apps, and holds an engineering degree from Santa Clara University.

Dennis Rasmussen

Dennis Rasmussen

Principal Mechanical Engineer

Dennis brings over twenty years of design and high volume manufacturing experience in consumer electronics and medical devices, with over twenty five patents in both fields. As Sr. Mechanical Design Engineer, he was Ramon's first hire at blu eCigs development team. Before working at blu, Dennis worked at Axis surgical designing medical devices including an RF ablation device for spinal surgery and a orthoscopic camera for knee surgery.

Chris Myles

Chris Myles

Senior Systems Engineer (Part-Time)

Chris is a maker. He's created an extensive range of designs from high volume medical devices and consumer electronics to one-of-a-kind commissions and ptototypes. With his diverse skill set and a Mechatronic Masters from Stanford, he's created for Abbot, blu, LimeLab, AliverCor and many others.

Adam Hoffman, PhD

Adam Hoffman, PhD

Electrical Engineer (Consultant)

Adam brings to the table a diverse experience in medical devices and consumer electronics. He has created electronics for, among other things, hospital beds, automated blood diagnostics machines, implantable tissue expanders, vaporizers, and surgical robots; at companies such as Hill-Rom, Abbott, blu, and Verb Surgical. He has a PhD in Life Sciences from Indiana State University, and a Master's in Electrical and Computer Engineering from Rose-Hulman Institute of Technology.

Amjad Huda

Amjad Huda

Consulting Financial Advisor

Amjad was co-founder of Sun Hydrogen and WaferGen Biosystems. He took WaferGen Biosystems public (NASDAQ: WGBS) and held CFO and COO positions. He has over 20 years of experience in finance, operations, technology, consulting, engineering and project management. He has worked for KPMG, PwC, Nortel Networks, and Kraft Foods.

Keith Emmons, M.D., MPH

Keith Emmons, M.D., MPH

Advisor, Healthcare + Research

A former general surgeon, Dr. Emmons uniquely blends practice with business and its ability to scale. He is also president of Medical Systems Management, assissting physician organizations to move into Managed Care. Previous leadership roles include SoCal Medical Director for United HealthCare, Senior Medical Director of California for Aetna Life Insurance, Treasurer of the Golden State Medical Society, Board of the National Medical Association, among many, many other posts and achievements.

Steven Brown, PhD

Steven Brown, PhD

Advisor, Science + Safety

Steven is a strategic leader with a broad range of experience spanning specialty chemical, pharmaceutical, and consumer packaged goods industries. His expertise is focused on technology innovation, product development and commercialization, defining IP strategies, and maximizing impact of R&D. Steven earned his Ph.D. in physical chemistry from Clarkson University – Center for Advanced Material Processing. He currently serves as Vice President of Technology for a private company in North Carolina.

Todd Manley

Todd Manley


Todd is an expert in M&A, strategy, and business operations. He has over 17 years of experience in Corporate Development delivering deals with a total value of approximately $55B and cost synergies of $5B. Todd has been instrumental in Post-Merger Integration, from creating Integration Management Office playbooks, to building an Employee Experience for onboarding acquired employees and driving top-line growth. His business operations and transformation experiences span accelerating time-to-market for new products, leading Privacy readiness for GDPR, and delivering operational efficiencies. Todd has also served as an Adjunct Lecturer at Santa Clara University and holds a BA from Stanford University and an MBA from Santa Clara University.

Anna Pond, MPA

Anna Pond, MPA

Advisor, Research Funding

Anna is a highly experienced consultant in the fields of nonprofits, foundations, and higher education, with over 25 years of experience. She has contributed to numerous successful projects, including strategic planning and has published on a range of topics. Anna has a background in nonprofit leadership development, earned her BA in Philosophy from Yale College and her MPA from Harvard Kennedy School of Government, and serves on various boards and committees.

William True, PhD

William True, PhD

Advisor, Regulatory

Bill is a futurist and creative technology leader. An e-vapor aerosol and e-liquid pioneer with deep M&A experience. Bill was the Chief Health, Science, and Technology Officer at the Foundation for a Smoke-Free World. As CTO of Fontem Ventures and SVP of R&D at Lorillard, he led technology innovations as well as the development of regulatory science and compliance infrastructure. Bill has a Ph.D. in Organic CHemistry from Vanderbilt.


Kazu by Wellness Insight Technologies, Inc.
Simple Agreement for Future Equity
Class B Common Stock

Most Recent Fiscal Year-End

Prior Fiscal Year-End

Total Assets



Cash & Cash Equivalents



Accounts Receivable



Short-Term Debt



Long-Term Debt



Revenue & Sales



Costs of Goods Sold



Taxes Paid



Net Income



What is a SAFE Agreement?

A Crowdfunding Simple Agreement for Future Equity (Crowdfunding SAFE) offers you the right to receive Class B Common Stock in Kazu by Wellness Insight Technologies, Inc.. The amount of Class B Common Stock you will receive in the future will be determined at the next equity round in which the Company raises at least $3,000,000.00 in a qualified equity financing. The highest conversion price per security is set based on a $16,035,886.35 Valuation Cap or if less, then you will receive a 15.00% discount on the price the new investors are paying. You will receive no interest on your investment. When the maturity date is reached, if the Crowdfunding SAFE has not converted then you are entitled to receive Class B Common Stock equal to your investment back at a price per security by dividing the Valuation Cap by the aggregate number of outstanding equity securities of the Company as of immediately prior (on a fully diluted basis).

Voting Proxy for Underlying Security of the CrowdFunding SAFE Sold in this Offering

As a condition to the purchase of this instrument, upon the issuance of shares of the Crowdfunding Stock (the “Securities”), the Investor agrees that the appointment of the Chief Executive Officer of the Company (the “CEO”), or his or her successor, is appointed as the Investor’s true and lawful proxy and attorney, with the power to act alone and with full power of substitution, to, consistent with this instrument and on behalf of the Investor, (i) vote all Securities, at any time and from time, on any matter for which approval of the holders of the Company’s stock is sought or upon which such holders are otherwise entitled to vote or consent (ii) give and receive notices and communications, (iii) execute any instrument or document that the CEO determines is necessary or appropriate in the exercise of its authority under this instrument, and (iv) take all actions necessary or appropriate in the judgment of the CEO for the accomplishment of the foregoing. The proxy and power granted by the Investor pursuant to this Section are coupled with an interest. Such proxy and power will be irrevocable. The proxy and power, so long as the Investor is an individual, will survive the death, incompetency and disability of the Investor and, so long as the Investor is an entity, will survive the merger or reorganization of the Investor or any other entity holding the Securities. However, the proxy will terminate upon the closing of a firm commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933 covering the offer and sale of Common Stock or the effectiveness of a registration statement under the Securities Exchange Act of 1934 covering the Common Stock. The provisions of this Section 3 shall survive the termination or expiration of this instrument in accordance with its term.

Investment Incentives*

Time-Based Perks:

Friends and Family (first 96 hours)

30% lifetime discount on Kazu pods, lifetime free subscription to Premium app features, 1 Kazu device, and 1 Kazu T-shirt

Super Early Bird (within the first week)

20% lifetime discount on Kazu pods, 1-year free subscription to Premium app features, 1 Kazu device, and 1 Kazu T-shirt

Early Bird Bonus (within the first 2 weeks)

10% lifetime discount on Kazu pods, 1-year free subscription to Premium app features, first access to purchase a Kazu device, and 1 Kazu T-shirt

Volume-Based Perks:

Nourishment ($500+)

First access to purchase a Kazu device, and 1 Kazu T-shirt!

Wellness ($1000+)

10% lifetime discount on Kazu pods, first access to purchase a Kazu device, and 1 Kazu T-shirt!

Rejuvenation ($2,500+)

20% lifetime discount on Kazu pods, 1-year free subscription to Premium app features, 1 Kazu device, and 1 Kazu T-shirt!

Radiance ($5,000+)

30% lifetime discount on Kazu pods, 1-year free subscription to Premium app features, 1 Kazu device, and 1 Kazu T-shirt

Harmony ($10,000+)

40% lifetime discount on Kazu pods, lifetime free subscription to Premium app features, an invitation to participate in beta-group for new feature releases, 1 Founder’s Series Kazu device, and 1 Kazu T-shirt

Nirvana ($25,000+)

50% lifetime discount on Kazu pods, lifetime free subscription to Premium app features, an invitation to participate in beta-group for new feature releases, 1 Founder’s Series Kazu device, 1 Kazu T-shirt, and an annual call with the CEO

*Physical perks may only be shipped to destinations within the United States.

*T-shirts and CEO calls available when the offering is fully completed.

*Pods and devices available upon market introduction.

*Discounts on pods are for personal use only. Discounts apply only to purchases made through the Company’s e-commerce site, do not apply to group/bulk purchases, do not apply to any third-party products that may be sold via the Company’s e-commerce site, and are not transferable.

*Premium subscription app features will be released after the initial release of the app and are not yet available. Subscriptions begin upon the release of paid subscription features.

*Beta-test participants must be willing to provide helpful feedback. Persons or entities with conflicts of interest with the Company may be excluded from participation.

*In order to receive perks from an investment, one must submit a single investment in the same offering that meets the minimum perk requirement. All perks occur when the offering is completed.

Irregular Use of Proceeds

The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Vendor payments.



Kazu begins development with supplement thought to protect against Alzheimer's and Parkinson's

We have begun to formulate Astaxanthin for use in Kazu pods. Astaxanthin is a chemical found naturally in certain plants and animals. Astaxanthin is an antioxidant, meaning it helps reduce oxidation. By reducing oxidation in the brain, it may protect against Alzheimer's and Parkinson's diseases. Astaxanthin can also reduce inflammation. As such, it might be useful as a treatment for problems such as rheumatoid arthritis. Laboratory research has also found that an extract from algae that makes astaxanthin slowed the growth of breast and skin cancer cells. Astaxanthin may also lower blood pressure and may stimulate the immune system. One small study showed astaxanthin combined with saw palmetto increased testosterone, which could help libido.*

Most of the small research studies to date have used between 2 mg and 12 mg daily. However, optimal doses of astaxanthin have not been determined. That’s where Kazu comes in. With its patented ability to deliver precise, personalized doses in the 0 to 30mg range, Kazu is the perfect tool for controlling and trialing different Astaxanthin doses. We hope Kazu can eventually lead to a better understanding of optimal astaxanthin doses.

 If you haven’t done so yet, invest today at


Ramon Alarcon, CEO



Reminder: Live discussion with Ramon Alarcon, CEO

The campaign is closing soon. Join us for a wide-ranging conversation about Kazu. Hear the latest updates and get your questions answered.

We’ll be talking live on Zoom on April 27th at 3pm ET / 12pm PT.

 If you haven’t done so yet, invest today at


Ramon Alarcon, CEO


Join live discussion with Ramon Alarcon, CEO

Still on the fence about Kazu? We'd love to help you make your decision. Already an investor? We want to hear from you too! Join us for a wide-ranging conversation about Kazu. Hear the latest updates and get your questions answered. 

We’ll be talking live on Zoom on April 27th at 3pm ET / 12pm PT. 

 If you haven’t done so yet, invest today at


Ramon Alarcon, CEO


Health professional recommends Kazu

In addition to the 170 CBD users we surveyed, we also talked with a number of health professionals. We included them in our market research to better understand the problems professionals experience when working with medicines and supplements, refine the Kazu value proposition, and gauge interest. It’s exciting when interviewees really get the potential of what we’re doing. Here are highlights from an interview session with Dr. Darla Booth, a chiropractor and functional medicine doctor.

 If you haven’t done so yet, invest today at


Ramon Alarcon, CEO


Kazu Develops New Feature to Promote Medication Adherence

According to the World Health Organization, people that are required to take over 2 medications only do so 67% of the time.* Medication adherence is a huge problem, which explains why some people achieve less than optimal results from their medicines. 

Kazu is proud to announce the development of a new scheduling feature to promote better adherence! Our scheduler goes beyond existing medicinal calendar apps by automatically sending your precise dose information to the device where it can be immediately dispensed. Also, unlike other apps, once a dose is taken, a dose confirmation is automatically recorded. This helps ensure the correct dose is taken and reduces the friction of the medication process in order to promote better adherence.

If you haven’t done so yet, invest today at


Ramon Alarcon, CEO



Kazu Market Research Uncovers New Insights

We surveyed over 170 CBD users and conducted market research interviews to better understand the problems people experience with medicines and supplements, refine the Kazu value proposition, and gauge consumer interest. It’s exciting when interviewees really get the potential of what we’re doing and can see the opportunities beyond the prompts and prototypes we show them. Here’s an excerpt from one such interview session.

 If you haven’t done so yet, invest today at


Ramon Alarcon, CEO


What ChatGPT says about dosing CBD

I wondered what ChatGPT would say about CBD. I expected it would provide an answer that’s reflective of the commonly accepted understanding about CBD. Its answer exemplifies the problem with how we go about dosing CBD. I’ve provided my commentary in italics below to highlight these problems.


How do people go about figuring out the best dose of CBD to help them relieve stress?


Finding the best CBD dosage to relieve stress can be a personal process as it varies from person to person. Here are some general tips that may help:

Start low and go slow: It's recommended to start with a low dose of CBD, usually around 10mg, and gradually increase the dose over time as needed. This allows you to monitor how your body responds to the CBD and adjust the dosage accordingly. 

10mg of one brand may behave completely differently than 10mg of another. What does gradually mean? A weeklong period? Month long? By how much should you adjust the dosage each time?

Consider your body weight: As a general rule of thumb, the heavier the person, the higher the dosage they may require. A good starting point for most people is around 1-6mg of CBD per 10 pounds of body weight.

So if you weigh 180 lbs, that could be 18mg or 114mg. Are you sure? That’s a huge range! And I thought you just said to start with 10mg? 

Look for high-quality products: Make sure you're using high-quality CBD products from reputable sources. Check the label for information on the concentration of CBD per serving size.

How do you know if something is high-quality? Are there test results you should look for? What’s a good concentration? 

Remember that CBD affects each person differently, and finding the right dosage may take some trial and error. Be patient and listen to your body as you find the best dosage for you.

How long should you expect this process to take? How patient can we expect consumers to be? What tools are available to guide consumers through the process?

You can see that the commonly practiced CBD dosing methodology is a mess. No wonder many consumers don’t have positive experiences! That’s where Kazu comes in. Kazu provides a tool to do the calculations for you, automatically track your progress, and make sure you understand how to achieve optimal results with CBD.

If you haven’t done so yet, invest today at


Ramon Alarcon, CEO


Why some drugs work better under the tongue

Sublingual administration involves placing a drug under the tongue, where it is absorbed directly into the bloodstream through the mucous membrane. This method of drug administration can result in more rapid and efficient absorption of certain drugs because the sublingual mucosa contains a rich network of blood vessels, allowing the drug to bypass the digestive system and liver metabolism, which can reduce the amount of drug that reaches systemic circulation.

Sublingual administration can also be used when a drug, like CBD, has poor oral bioavailability, meaning that it is not well absorbed by the gut or may be rapidly metabolized in the liver, resulting in lower levels reaching your blood stream.

Kazu is perfect for sublingual administration. The shape of our pod directs droplets directly to the part of your mouth where absorption can occur the fastest. And the Kazu device has a built-in timer, helping you know how long to hold the CBD under your tongue for best results.

 If you haven’t done so yet, invest today at


Ramon Alarcon, CEO


US Patent and Trademark office allows 2 more trademarks for Kazu

On April 4th, we were granted two trademarks, 97033327 and 97135104, to be used with our Kazu branded platform by the US Patent and Trademark Office. This marks an important milestone for the company, as it provides legal protection for the company's intellectual property and helps prevent brand confusion.

Trademarks are an essential asset for businesses as they create a unique identity for their products or services. They protect the company's brand and helps customers identify its products easily. Furthermore, trademarks add value to a company's brand equity by enhancing its reputation and making it more recognizable and memorable to customers

The allowance of these two trademarks is an excellent development for the company and its investors. It adds to the company’s growing intellectual property portfolio that already includes several patents, trademarks, copyrights and trade secrets. This further strengthens our competitive position in the market. 

If you haven’t done so yet, invest today at


Ramon Alarcon, CEO


Study found melatonin content of supplements varied by 465%

A recent study showed the melatonin content found across 31 supplements ranged from 83% less than advertised up to 478% more than advertised.* That’s a huge discrepancy! So, it makes sense when you hear people say, “melatonin doesn’t work for me.” Taking too little would be ineffective and taking too much can lead to side effects that actually make it more difficult to sleep. And since the FDA doesn’t regulate dietary supplements, consumers need to be aware of the potential differences from brand to brand.

Kazu offers a better way. Each batch of formulation is tested for potency and Kazu pods are programmed with this batch information. This means that even if there are slight variations from batch-to-batch, Kazu can automatically compensate and provide consumers with the precise amount of melatonin they expect. This patented feature enables Kazu to achieve an accuracy of +/- 3%.** It makes sense that taking the right amount can make all the difference, and potentially help some consumers avoid feeling the need to move to more problematic drugs like Ambien. 

If you haven’t done so yet, invest today at


Ramon Alarcon, CEO


** Based on reference dose of 10mg


Multiple investments in an offering cannot be combined to qualify for a larger campaign perk. Get rewarded for investing more into Kazu by Wellness Insight Technologies, Inc..



Ramon Alarcon

Kazu by Wellness Insight Technologies, Inc.

3 months ago

There was a little miscommunication between us and StartEngine today regarding our updates. The one that was scheduled to go out Thursday went out today. Our website will not start taking reservations for Kazu until this Thursday. Sorry for any confusion!



George Pohle

3 months ago

Whats the revenue model and structure for the business? Whats your revenue target for year 5 (or latest projections)?



W Kim Colich


3 months ago

Hi, You say "We have 10 issued and pending patents". How many of these 10 have been issued? Are the ones that have been granted assigned to Kazu? How long ago were the others submitted? Thanks for clarifying this. Also to the right of your "A solution for everyone" pitch, you have misspelled "enabled" - there shouldn't be a "d" after the "n"... :-) Blessings




Cancel anytime before 48 hours before a rolling close or the offering end date.



We want you to succeed and get the most out of your money by offering rewards and memberships!


Your info is your info. We take pride in keeping it that way!


Invest in over 200 start-ups and collectibles!

With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.

With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.

At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.

Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.

StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.

For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.

For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.

Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.

Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.

Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.


@ 2022 All Rights Reserved

Apple Store Logo

Get To Know Us

Our Team



Important Message


Unless indicated otherwise with respect to a particular issuer, all securities-related activity is conducted by regulated affiliates of StartEngine: StartEngine Capital, LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and here as a member of the Financial Industry Regulatory Authority (FINRA), or StartEngine Primary, LLC, a broker-dealer registered with the SEC and FINRA/SIPC . You can review the background of our broker-dealer and our investment professionals on FINRA’s BrokerCheck here. StartEngine Secondary is an alternative trading system regulated by the SEC and operated by StartEngine Primary, LLC, a broker dealer registered with the SEC and FINRA. StartEngine Primary, LLC is a member of SIPC and explanatory brochures are available upon request by contacting SIPC at (202) 371-8300.

Investment opportunities posted and accessible through the site are of three types:

1) Regulation A offerings (JOBS Act Title IV; known as Regulation A+), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Primary, LLC (unless otherwise indicated). 2) Regulation D offerings (Rule 506(c)), which are offered only to accredited investors. These offerings are made through StartEngine Primary, LLC. 3) Regulation Crowdfunding offerings (JOBS Act Title III), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Capital, LLC. Some of these offerings are open to the general public, however there are important differences and risks.

Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. StartEngine and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice with respect to any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. StartEngine does not verify the adequacy, accuracy or completeness of any information. Neither StartEngine nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site. See additional general disclosures here.

By accessing this site and any pages on this site, you agree to be bound by our Terms of use and Privacy Policy, as may be amended from time to time without notice or liability.

Canadian Investors Investment opportunities posted and accessible through the site will not be offered to Canadian resident investors. Potential investors are strongly advised to consult their legal, tax and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.

California Investors Only – Do Not Sell My Personal Information (800-317-2200). StartEngine does not sell personal information. For all customer inquiries, please write to

StartEngine’s Reg A+ offering is made available through StartEngine Crowdfunding, Inc. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For more information about this offering, please view StartEngine’s offering circular and risk associated with this offering.